Last reviewed · How we verify
LAIV followed by TIV
At a glance
| Generic name | LAIV followed by TIV |
|---|---|
| Also known as | Seasonal Influenza Vaccines |
| Sponsor | University of Rochester |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
- Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection (PHASE1)
- Woodsmoke Exposure, Influenza Infection, and Nasal Immunity (PHASE4)
- Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children (PHASE4)
- Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine (PHASE1)
- The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (PHASE1)
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (PHASE1)
- Efficacy & Safety of Nasal Influenza Immunisation in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAIV followed by TIV CI brief — competitive landscape report
- LAIV followed by TIV updates RSS · CI watch RSS
- University of Rochester portfolio CI